Rachel D Aufforth1, Pooja Ramakant1, Samira M Sadowski1, Amit Mehta1, Katarzyna Trebska-McGowan1, Naris Nilubol1, Karel Pacak1, Electron Kebebew1. 1. Endocrine Oncology Branch (R.D.A. S.M.S., N.N., E.K.), National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892; Endocrine Surgery Department (P.R.), Christian Medical College, Vellore, India; Geisel School of Medicine (A.M.), Hanover, New Hampshire; Thoracic and Gastrointestinal Oncology Branch (K.T.-M.), National Cancer Institute, Bethesda, Maryland; and Program in Reproductive and Adult Endocrinology (K.P.), Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892.
Abstract
CONTEXT: Patients with von Hippel-Lindau (VHL) syndrome have a 25-30% chance of developing pheochromocytoma. Although practice guidelines recommend biochemical and radiological screening every 1-2 years for pheochromocytoma in patients with VHL, there are limited data on the optimal age and frequency for screening. OBJECTIVE: Our objective was to determine the earliest age of onset and frequency of contralateral and recurrent pheochromocytomas in patients with VHL syndrome. METHODS: This is a retrospective analysis of a prospective cohort of patients with VHL enrolled in a natural history study. RESULTS: A total of 273 patients diagnosed with VHL were enrolled in a natural history clinical study. Thirty-one percent (84) were diagnosed with pheochromocytoma. The mean age of diagnosis was 28.8 ± 13.9 years. The earliest age at diagnosis was 5.5 years. Median follow-up for the cohort was 116.6 months (range, 0.1-613.2). Ninety-nine percent (83) of patients underwent adrenalectomy. Fifty-eight and 32% of patients had metanephrines and/or catecholamines elevated more than two times and more than four times the upper limit of normal, respectively. Twenty-five percent (21) of pheochromocytomas were diagnosed in pediatric patients younger than 19 years of age, and 86% and 57% of pediatric patients had an elevation more than two times and more than four times upper limit of normal, respectively. Eight patients had a total of nine recurrences. The median age at recurrence was 33.5 years (range, 8.8-51.9). Recurrences occurred as short as 0.5 years and as long as 39.7 years after the initial operation. CONCLUSIONS: Our findings among VHL pediatric patients supports the need for biochemical screening starting at age 5 with annual lifelong screening.
CONTEXT: Patients with von Hippel-Lindau (VHL) syndrome have a 25-30% chance of developing pheochromocytoma. Although practice guidelines recommend biochemical and radiological screening every 1-2 years for pheochromocytoma in patients with VHL, there are limited data on the optimal age and frequency for screening. OBJECTIVE: Our objective was to determine the earliest age of onset and frequency of contralateral and recurrent pheochromocytomas in patients with VHL syndrome. METHODS: This is a retrospective analysis of a prospective cohort of patients with VHL enrolled in a natural history study. RESULTS: A total of 273 patients diagnosed with VHL were enrolled in a natural history clinical study. Thirty-one percent (84) were diagnosed with pheochromocytoma. The mean age of diagnosis was 28.8 ± 13.9 years. The earliest age at diagnosis was 5.5 years. Median follow-up for the cohort was 116.6 months (range, 0.1-613.2). Ninety-nine percent (83) of patients underwent adrenalectomy. Fifty-eight and 32% of patients had metanephrines and/or catecholamines elevated more than two times and more than four times the upper limit of normal, respectively. Twenty-five percent (21) of pheochromocytomas were diagnosed in pediatric patients younger than 19 years of age, and 86% and 57% of pediatric patients had an elevation more than two times and more than four times upper limit of normal, respectively. Eight patients had a total of nine recurrences. The median age at recurrence was 33.5 years (range, 8.8-51.9). Recurrences occurred as short as 0.5 years and as long as 39.7 years after the initial operation. CONCLUSIONS: Our findings among VHL pediatric patients supports the need for biochemical screening starting at age 5 with annual lifelong screening.
Authors: Dmitry Volkin; Nitin Yerram; Faisal Ahmed; Dawud Lankford; Angelo Baccala; Gopal N Gupta; Anthony Hoang; Jeffrey Nix; Adam R Metwalli; David M Lang; Gennady Bratslavsky; W Marston Linehan; Peter A Pinto Journal: J Pediatr Surg Date: 2012-11 Impact factor: 2.545
Authors: I R Maddock; A Moran; E R Maher; M D Teare; A Norman; S J Payne; R Whitehouse; C Dodd; M Lavin; N Hartley; M Super; D G Evans Journal: J Med Genet Date: 1996-02 Impact factor: 6.318
Authors: Sabine Schmid; Silke Gillessen; Isabelle Binet; Michael Brändle; Daniel Engeler; Jeannette Greiner; Claudia Hader; Karl Heinimann; Patrik Kloos; Willy Krek; Ina Krull; Sandro J Stoeckli; Michael C Sulz; Karin van Leyen; Johannes Weber; Christian Rothermundt; Thomas Hundsberger Journal: Oncol Res Treat Date: 2014-11-17 Impact factor: 2.825
Authors: E R Maher; L Iselius; J R Yates; M Littler; C Benjamin; R Harris; J Sampson; A Williams; M A Ferguson-Smith; N Morton Journal: J Med Genet Date: 1991-07 Impact factor: 6.318
Authors: S Richard; C Beigelman; J M Duclos; J P Fendler; H Plauchu; P F Plouin; F Resche; M Schlumberger; B Vermesse; C Proye Journal: Surgery Date: 1994-12 Impact factor: 3.982
Authors: Birke Bausch; Ulrich Wellner; Dirk Bausch; Francesca Schiavi; Marta Barontini; Gabriela Sanso; Martin K Walz; Mariola Peczkowska; Georges Weryha; Patrizia Dall'igna; Giovanni Cecchetto; Gianni Bisogno; Lars C Moeller; Detlef Bockenhauer; Attila Patocs; Karoly Rácz; Dmitry Zabolotnyi; Svetlana Yaremchuk; Iveta Dzivite-Krisane; Frederic Castinetti; David Taieb; Angelica Malinoc; Ernst von Dobschuetz; Jochen Roessler; Kurt W Schmid; Giuseppe Opocher; Charis Eng; Hartmut P H Neumann Journal: Endocr Relat Cancer Date: 2013-12-16 Impact factor: 5.678
Authors: J Crespigio; L C L Berbel; M A Dias; R F Berbel; S S Pereira; D Pignatelli; T L Mazzuco Journal: J Endocrinol Invest Date: 2017-06-06 Impact factor: 4.256
Authors: Thomas Sanford; Patrick T Gomella; Rashid Siddiqui; Daniel Su; Julie Y An; Gennady Bratslavsky; Mark W Ball; W Marston Linehan; Adam R Metwalli Journal: Urol Oncol Date: 2020-12-08 Impact factor: 2.954